3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Thoracic
1
Plasma cell
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
12
Small Cell Lung Carcinoma
4
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Mesothelioma
2
Thymoma
1
Somatostatinoma
1
Recurrence
1
Pheochromocytoma
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Insulinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Glucagonoma
1
Gastrointestinal Neoplasms
1
Gastrinoma
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Medullary
1
Carcinoma, Large Cell
1
Carcinoma, Islet Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
42
Carboplatin
24
Cyclophosphamide
20
Paclitaxel
19
Nivolumab
17
Cisplatin
15
fludarabine
14
Gemcitabine
12
aldesleukin
10
Docetaxel
10
Bevacizumab
9
Magnetic Resonance Spectroscopy
8
Trastuzumab
7
Specimen Handling
7
Drug Therapy
7
Pemetrexed
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Fluorouracil
6
Cetuximab
6
Blood Specimen Collection
6
sargramostim
5
pegfilgrastim
5
avelumab
5
Topotecan
5
Taxes
5
Irinotecan
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Everolimus
×
Thoracic
×
Clear all
NCT02407509
2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1
Completed
104 enrolled